Filing summary: Synaptogenix, Inc. — Q1 2023
Entity note: The request metadata identifies TAO Synergies Inc., but the supplied Form 10-Q is for Synaptogenix, Inc. (Nasdaq: SNPX), for the quarter ended March 31, 2023. This summary reflects the filing provided.
Business context and reporting period
Synaptogenix is a clinical-stage biopharmaceutical company focused primarily on Bryostatin-1 for Alzheimer’s disease (AD), with potential development programs in Fragile X syndrome, multiple sclerosis and other conditions. The unaudited financial statements compare the three months ended March 31, 2023 with the same period in 2022.
Financial position and results
- Revenue: No revenue is reported.
- Operating expenses: $2.92 million, down 11.0% from $3.28 million. Research and development expense fell 40.9% to $877,717; general and administrative expense rose 13.8% to $2.04 million.
- Loss: Net loss was $1.71 million, compared with $3.28 million. After $266,074 of preferred dividends, net loss attributable to common stockholders was $1.98 million, or $0.26 per share, versus $3.28 million, or $0.47 per share.
- Other income: $1.21 million, including $396,357 of interest income and noncash fair-value gains of $588,000 on warrant liabilities and $225,800 on an embedded derivative.
- Cash flow: Operating cash use was $1.70 million; investing cash use was $2,038; financing cash flow was zero. Cash and cash equivalents declined $1.70 million during the quarter.
- Cash and liquidity: Cash and cash equivalents were $35.78 million at quarter-end, down from $37.48 million at December 31, 2022. Working capital was $35.23 million, versus $37.27 million at year-end. Management said approximately $35 million of cash as of the report date was expected to fund projected operating requirements for at least 12 months.
- Liabilities and preferred stock: Total liabilities were $2.34 million, including $1.28 million of current liabilities, a $922,000 warrant liability and a $144,500 derivative liability. Separately, 15,000 Series B preferred shares have a $15 million liquidation preference and 7% annual dividends; the filing reports $381,964 of accrued dividends at March 31.
Material changes versus the prior period
- Net loss narrowed by 47.8%, mainly as AD trial-related R&D expense declined; G&A expense increased.
- Interest income rose substantially with higher money-market rates. Fair-value gains on warrants and the preferred-stock derivative also reduced reported loss; these are noncash and depend on valuation assumptions.
- Operating cash use improved from $3.49 million to $1.70 million. The comparison was affected by lower trial spending and noncash fair-value changes.
- Common shares issued and outstanding increased from 7,267,032 at year-end to 7,359,871 at March 31. The weighted-average share count used for Q1 loss per share was 7,501,400.
Outlook, developments and risks
- The confirmatory Phase 2 AD study did not meet its primary endpoint. The company reported that secondary endpoints were not statistically significant in the overall population or the low-to-moderately severe subgroup. It reported statistical significance on nearly all prespecified secondary endpoints in a severe AD subgroup with MMSE-2 baseline scores of 10–14, plus positive exploratory and post hoc analyses.
- The company terminated its open-label, dose-ranging Phase 2 study in December 2022; cumulative related expense was approximately $1.5 million. It said it was evaluating how to proceed with other development programs.
- The Fragile X IND was on FDA clinical hold pending additional pharmacokinetic and pharmacodynamic analytics. The Cleveland Clinic collaboration for multiple sclerosis remained at an early development stage.
- The Series B preferred stock is subject to redemption in 15 equal monthly installments beginning June 1, 2023. Depending on terms and limitations, payments may be made in cash or shares. The preferred stock carries a 7% compounded annual dividend, potentially increasing to 15% upon a triggering event, and is subject to covenants and potential dilution. The related warrants include full-ratchet price adjustment provisions.
- Management expects to need additional capital for further development beyond current plans. Financing may be unavailable or dilutive, may carry restrictive terms, or may require the company to surrender technology or product rights.
- Risks include clinical and regulatory uncertainty, limited bryostatin supply, reliance on licensors and collaborators, possible trial delays, and indemnification obligations related to the company’s spin-off. The filing states no indemnification claims were pending as of the reporting date.
- After quarter-end, Nasdaq notified the company that its stock had failed the $1.00 minimum bid-price requirement; the stated compliance deadline was October 23, 2023. Stockholder approval for certain potential share issuances related to the preferred financing was obtained April 14, 2023.
- Disclosure controls and procedures were deemed ineffective at March 31, 2023 because of material weaknesses involving segregation of duties, financial-close and reporting processes, and IT general controls. Management nevertheless stated that the reported financial statements fairly present the company’s financial condition and results in all material respects.
Important facts for investors to verify
- Confirm that Synaptogenix, rather than TAO Synergies Inc., is the intended company and filing.
- Review the full preferred-stock and warrant terms, including redemption amounts and timing, cash-versus-share settlement limits, price adjustments, covenants and triggering-event remedies.
- Assess the subgroup AD findings alongside the failed primary endpoint, trial design, statistical analyses and any subsequent regulatory or clinical updates.
- Monitor cash use, trial and development spending, financing needs, and whether management’s stated 12-month liquidity expectation remains current.
- Check subsequent Nasdaq listing status, share issuance and dilution, and management’s progress in remediating the disclosed control weaknesses.